Helicobacter

Papers
(The H4-Index of Helicobacter is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Gastric Helicobacter pylori infection does not contribute to extraoral halitosis and its eradication cannot achieve substantial reduction of halitosis96
Issue Information93
Second‐ and Third‐Line Therapies for Helicobacter pylori Eradication in Slovenia: Data From 2013–2023 of the European Registry on 65
DNA starvation/stationary phase protection protein of Helicobacter pylori as a potential immunodominant antigen for infection detection53
UreBimmunodominant epitope‐specificCD8+T‐cell responses were beneficial in reducing gastric symptoms inHelicobacter pylori‐infected individuals52
A “new” option in Helicobacter pylori eradication: High‐dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting50
Expansion of cagA Copy Number in Helicobacter pylori During Co‐Infection in a Mouse Model50
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp‐ EuReg 49
Worldwide Phylogenetic and Clinical Risk Association of the Helicobacter pylori Outer Membrane Gen48
Low‐dose or high‐dose amoxicillin in vonoprazan‐based dual therapy for Helicobacter pylori eradication? A systematic review and meta‐analysis45
Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China43
A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy o41
Proteomic Profiling of Extracellular Vesicles Reveals Potential Biomarkers for Helicobacter pylori Infection and Gastric Cancer40
Evidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition39
Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta‐analysis of RCTs36
Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis35
34
Issue Information29
Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan—A 20‐year longitudinal follow‐up29
Droplet Digital PCR ‐Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts 26
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first‐line regimen for Helicobacter pylori eradication: A randomized controlled trial26
Letter to the Editor regarding the article: “Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy”25
Roles of Gastric Non‐Helicobacter pylori Helicobacter Species in Gastric Disease Development: A Review25
Nationwide survey ofHelicobacter pyloriseropositivity and gastric atrophy in Zambia24
Helicobacter pylori , Inflammation, and Long‐Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study24
0.18201804161072